Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation

A. John Camm, Fausto J. Pinto, Graeme J. Hankey, Felicita Andreotti, F. D.Richard Hobbs, A. John Camm, F. D. Richard Hobbs, László Csiba, Gabriel R. De Freitas, Shinya Goto, Carlos Cantú, Jorge Gonzalez-Zuelgaray, Werner Hacke, Han Hwa Hu, Lorenzo Mantovani, Byung Woo Yoon, Dayi Hu, Kui Hian Sim

研究成果: 雜誌貢獻回顧型文獻

30 引文 (Scopus)

摘要

Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Cardiology (ESC) guidelines for the management of AF, the Action for Stroke Prevention alliance writing group have identified key reasons for the suboptimal implementation of the guidelines at a global, regional, and local level, with an emphasis on access restrictions to guideline-recommended therapies. Following identification of these barriers, the group has developed an expert consensus on strategies to augment the implementation of current guidelines, including practical, educational, and access-related measures. The potential impact of healthcare quality measures for stroke prevention on guideline implementation is also explored. By providing practical guidance on how to improve implementation of the ESC guidelines, or region-specific modifications of these guidelines, the aim is to reduce the potentially devastating impact that stroke can have on patients, their families and their carers.
原文英語
頁(從 - 到)1007-1017
頁數11
期刊Europace
17
發行號7
DOIs
出版狀態已發佈 - 一月 1 2015

指紋

Practice Guidelines
Anticoagulants
Atrial Fibrillation
Stroke
Guidelines
Social Identification
Quality of Health Care
Cardiology
Health Care Costs
Caregivers
Registries
Consensus
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

引用此文

Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., Hobbs, F. D. R., John Camm, A., ... Sim, K. H. (2015). Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation. Europace, 17(7), 1007-1017. https://doi.org/10.1093/europace/euv068

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice : Barriers to and strategies for optimal implementation. / Camm, A. John; Pinto, Fausto J.; Hankey, Graeme J.; Andreotti, Felicita; Hobbs, F. D.Richard; John Camm, A.; Richard Hobbs, F. D.; Csiba, László; De Freitas, Gabriel R.; Goto, Shinya; Cantú, Carlos; Gonzalez-Zuelgaray, Jorge; Hacke, Werner; Hu, Han Hwa; Mantovani, Lorenzo; Yoon, Byung Woo; Hu, Dayi; Sim, Kui Hian.

於: Europace, 卷 17, 編號 7, 01.01.2015, p. 1007-1017.

研究成果: 雜誌貢獻回顧型文獻

Camm, AJ, Pinto, FJ, Hankey, GJ, Andreotti, F, Hobbs, FDR, John Camm, A, Richard Hobbs, FD, Csiba, L, De Freitas, GR, Goto, S, Cantú, C, Gonzalez-Zuelgaray, J, Hacke, W, Hu, HH, Mantovani, L, Yoon, BW, Hu, D & Sim, KH 2015, 'Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation', Europace, 卷 17, 編號 7, 頁 1007-1017. https://doi.org/10.1093/europace/euv068
Camm, A. John ; Pinto, Fausto J. ; Hankey, Graeme J. ; Andreotti, Felicita ; Hobbs, F. D.Richard ; John Camm, A. ; Richard Hobbs, F. D. ; Csiba, László ; De Freitas, Gabriel R. ; Goto, Shinya ; Cantú, Carlos ; Gonzalez-Zuelgaray, Jorge ; Hacke, Werner ; Hu, Han Hwa ; Mantovani, Lorenzo ; Yoon, Byung Woo ; Hu, Dayi ; Sim, Kui Hian. / Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice : Barriers to and strategies for optimal implementation. 於: Europace. 2015 ; 卷 17, 編號 7. 頁 1007-1017.
@article{fde944e0d2c4463f93c36dd49b301df4,
title = "Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: Barriers to and strategies for optimal implementation",
abstract = "Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Cardiology (ESC) guidelines for the management of AF, the Action for Stroke Prevention alliance writing group have identified key reasons for the suboptimal implementation of the guidelines at a global, regional, and local level, with an emphasis on access restrictions to guideline-recommended therapies. Following identification of these barriers, the group has developed an expert consensus on strategies to augment the implementation of current guidelines, including practical, educational, and access-related measures. The potential impact of healthcare quality measures for stroke prevention on guideline implementation is also explored. By providing practical guidance on how to improve implementation of the ESC guidelines, or region-specific modifications of these guidelines, the aim is to reduce the potentially devastating impact that stroke can have on patients, their families and their carers.",
keywords = "Atrial fibrillation, Guidelines, Oral anticoagulants, Stroke prevention",
author = "Camm, {A. John} and Pinto, {Fausto J.} and Hankey, {Graeme J.} and Felicita Andreotti and Hobbs, {F. D.Richard} and {John Camm}, A. and {Richard Hobbs}, {F. D.} and L{\'a}szl{\'o} Csiba and {De Freitas}, {Gabriel R.} and Shinya Goto and Carlos Cant{\'u} and Jorge Gonzalez-Zuelgaray and Werner Hacke and Hu, {Han Hwa} and Lorenzo Mantovani and Yoon, {Byung Woo} and Dayi Hu and Sim, {Kui Hian}",
year = "2015",
month = "1",
day = "1",
doi = "10.1093/europace/euv068",
language = "English",
volume = "17",
pages = "1007--1017",
journal = "Europace",
issn = "1099-5129",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice

T2 - Barriers to and strategies for optimal implementation

AU - Camm, A. John

AU - Pinto, Fausto J.

AU - Hankey, Graeme J.

AU - Andreotti, Felicita

AU - Hobbs, F. D.Richard

AU - John Camm, A.

AU - Richard Hobbs, F. D.

AU - Csiba, László

AU - De Freitas, Gabriel R.

AU - Goto, Shinya

AU - Cantú, Carlos

AU - Gonzalez-Zuelgaray, Jorge

AU - Hacke, Werner

AU - Hu, Han Hwa

AU - Mantovani, Lorenzo

AU - Yoon, Byung Woo

AU - Hu, Dayi

AU - Sim, Kui Hian

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Cardiology (ESC) guidelines for the management of AF, the Action for Stroke Prevention alliance writing group have identified key reasons for the suboptimal implementation of the guidelines at a global, regional, and local level, with an emphasis on access restrictions to guideline-recommended therapies. Following identification of these barriers, the group has developed an expert consensus on strategies to augment the implementation of current guidelines, including practical, educational, and access-related measures. The potential impact of healthcare quality measures for stroke prevention on guideline implementation is also explored. By providing practical guidance on how to improve implementation of the ESC guidelines, or region-specific modifications of these guidelines, the aim is to reduce the potentially devastating impact that stroke can have on patients, their families and their carers.

AB - Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Cardiology (ESC) guidelines for the management of AF, the Action for Stroke Prevention alliance writing group have identified key reasons for the suboptimal implementation of the guidelines at a global, regional, and local level, with an emphasis on access restrictions to guideline-recommended therapies. Following identification of these barriers, the group has developed an expert consensus on strategies to augment the implementation of current guidelines, including practical, educational, and access-related measures. The potential impact of healthcare quality measures for stroke prevention on guideline implementation is also explored. By providing practical guidance on how to improve implementation of the ESC guidelines, or region-specific modifications of these guidelines, the aim is to reduce the potentially devastating impact that stroke can have on patients, their families and their carers.

KW - Atrial fibrillation

KW - Guidelines

KW - Oral anticoagulants

KW - Stroke prevention

UR - http://www.scopus.com/inward/record.url?scp=84926611359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926611359&partnerID=8YFLogxK

U2 - 10.1093/europace/euv068

DO - 10.1093/europace/euv068

M3 - Review article

C2 - 26116685

AN - SCOPUS:84926611359

VL - 17

SP - 1007

EP - 1017

JO - Europace

JF - Europace

SN - 1099-5129

IS - 7

ER -